WO1996027378A3 - Use of penciclovir for the treatment of human herpes-virus-8 - Google Patents

Use of penciclovir for the treatment of human herpes-virus-8 Download PDF

Info

Publication number
WO1996027378A3
WO1996027378A3 PCT/EP1996/000933 EP9600933W WO9627378A3 WO 1996027378 A3 WO1996027378 A3 WO 1996027378A3 EP 9600933 W EP9600933 W EP 9600933W WO 9627378 A3 WO9627378 A3 WO 9627378A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
penciclovir
virus
human herpes
bioprecursor
Prior art date
Application number
PCT/EP1996/000933
Other languages
French (fr)
Other versions
WO1996027378A2 (en
Inventor
Klaus Max Esser
Hodge Richard Anthony Vere
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Klaus Max Esser
Hodge Richard Anthony Vere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK96907360T priority Critical patent/DK0814813T3/en
Priority to SI9630655T priority patent/SI0814813T1/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp, Klaus Max Esser, Hodge Richard Anthony Vere filed Critical Smithkline Beecham Plc
Priority to HU9800272A priority patent/HU226005B1/en
Priority to JP8526607A priority patent/JPH11501625A/en
Priority to NZ303951A priority patent/NZ303951A/en
Priority to BR9607663A priority patent/BR9607663A/en
Priority to AU51022/96A priority patent/AU701739B2/en
Priority to AT96907360T priority patent/ATE254919T1/en
Priority to CA2214406A priority patent/CA2214406C/en
Priority to EP96907360A priority patent/EP0814813B1/en
Priority to DE69630876T priority patent/DE69630876T2/en
Publication of WO1996027378A2 publication Critical patent/WO1996027378A2/en
Publication of WO1996027378A3 publication Critical patent/WO1996027378A3/en
Priority to MXPA/A/1997/006759A priority patent/MXPA97006759A/en
Priority to NO19974101A priority patent/NO317733B1/en
Priority to HK98103679A priority patent/HK1004373A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The use of a compound of formula (A) or a bioprecursor, or a pharmaceutically acceptable salt, phosphate ester and/or acyl derivative of either of the foregoing in the manufacture of a medicament for use in the treatment (including prophylaxis) of HHV-8 infection.
PCT/EP1996/000933 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8 WO1996027378A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CA2214406A CA2214406C (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8
AT96907360T ATE254919T1 (en) 1995-03-07 1996-03-05 USE OF PENCICLOVIR TO TREAT HUMAN HERPES VIRUS-8
HU9800272A HU226005B1 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8
SI9630655T SI0814813T1 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8
NZ303951A NZ303951A (en) 1995-03-07 1996-03-05 Use of penciclovir and famciclovire for treating human herpesvirus 8
BR9607663A BR9607663A (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes virus 8
EP96907360A EP0814813B1 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8
DK96907360T DK0814813T3 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes virus-8
JP8526607A JPH11501625A (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpesvirus-8
AU51022/96A AU701739B2 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8
DE69630876T DE69630876T2 (en) 1995-03-07 1996-03-05 USE OF PENCICLOVIR FOR THE TREATMENT OF HUMAN HERPES VIRUS-8
MXPA/A/1997/006759A MXPA97006759A (en) 1995-03-07 1997-09-05 Use of penciclovir for the treatment of herpes virus 8 hum
NO19974101A NO317733B1 (en) 1995-03-07 1997-09-05 Use of penciclovir for the treatment of human herpes virus-8
HK98103679A HK1004373A1 (en) 1995-03-07 1998-04-29 Use of penciclovir for the treatment of human herpes-virus-8

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9504497.0A GB9504497D0 (en) 1995-03-07 1995-03-07 Pharmaceuticals
GB9504497.0 1995-03-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/473,888 Continuation US6489330B1 (en) 1995-03-07 1999-12-29 Use of penciclovir for the treatment of human herpes-virus-8

Publications (2)

Publication Number Publication Date
WO1996027378A2 WO1996027378A2 (en) 1996-09-12
WO1996027378A3 true WO1996027378A3 (en) 1997-01-16

Family

ID=10770731

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/000933 WO1996027378A2 (en) 1995-03-07 1996-03-05 Use of penciclovir for the treatment of human herpes-virus-8

Country Status (23)

Country Link
US (1) US6489330B1 (en)
EP (1) EP0814813B1 (en)
JP (2) JPH11501625A (en)
KR (1) KR19980702833A (en)
CN (1) CN1138545C (en)
AT (1) ATE254919T1 (en)
AU (1) AU701739B2 (en)
BR (1) BR9607663A (en)
CA (1) CA2214406C (en)
CY (1) CY2525B1 (en)
CZ (1) CZ293470B6 (en)
DE (1) DE69630876T2 (en)
DK (1) DK0814813T3 (en)
ES (1) ES2211949T3 (en)
GB (1) GB9504497D0 (en)
HK (1) HK1004373A1 (en)
HU (1) HU226005B1 (en)
NO (1) NO317733B1 (en)
NZ (1) NZ303951A (en)
PT (1) PT814813E (en)
TR (1) TR199700921T1 (en)
WO (1) WO1996027378A2 (en)
ZA (1) ZA961795B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010503710A (en) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド Treatment of liver damage by administration of receptor-related protein (RAP) conjugates
CA2721148A1 (en) * 2008-04-11 2009-10-15 Epiphany Biosciences, Inc. Treatment and/or prevention of multiple sclerosis
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927A2 (en) * 1983-08-18 1985-05-22 Beecham Group Plc Antiviral guanine derivatives
EP0182024A2 (en) * 1984-09-20 1986-05-28 Beecham Group Plc Purine derivatives and their pharmaceutical use
EP0216459A1 (en) * 1985-07-27 1987-04-01 Beecham Group Plc 9-Substituted guanine monohydrates

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU635642B2 (en) 1990-05-24 1993-03-25 E.R. Squibb & Sons, Inc. Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines
GB9015051D0 (en) 1990-07-07 1990-08-29 Beecham Group Plc Pharmaceutical treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927A2 (en) * 1983-08-18 1985-05-22 Beecham Group Plc Antiviral guanine derivatives
EP0182024A2 (en) * 1984-09-20 1986-05-28 Beecham Group Plc Purine derivatives and their pharmaceutical use
EP0216459A1 (en) * 1985-07-27 1987-04-01 Beecham Group Plc 9-Substituted guanine monohydrates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
M. LUPPI ET AL.: "The new lymphotrophic herpesviruses (HHV-6, HHV-7 and HHV-8) and hepatitis C virus (HCV) in human lymphoproliferative diseases: an overview.", HAEMATOLOGICA, vol. 81, no. 3, 1996, pages 265 - 281, XP000609248 *
M.R. BOYD ET AL.: "Penciclovir: a review of its spectrum of activity, selectivity, and cross-resistance pattern.", ANTIVIRAL CHEM. CHEMOTHER. SUPPL., vol. 4, no. 1, 1993, pages 3 - 11, XP000609250 *

Also Published As

Publication number Publication date
EP0814813A2 (en) 1998-01-07
CZ293470B6 (en) 2004-05-12
WO1996027378A2 (en) 1996-09-12
ES2211949T3 (en) 2004-07-16
DK0814813T3 (en) 2004-03-22
JP2007297412A (en) 2007-11-15
HUP9800272A3 (en) 2000-12-28
HK1004373A1 (en) 1998-11-27
CA2214406A1 (en) 1996-09-12
NZ303951A (en) 1999-07-29
CZ283197A3 (en) 1998-02-18
JPH11501625A (en) 1999-02-09
NO317733B1 (en) 2004-12-13
DE69630876D1 (en) 2004-01-08
US6489330B1 (en) 2002-12-03
GB9504497D0 (en) 1995-04-26
ZA961795B (en) 1996-11-25
CN1183722A (en) 1998-06-03
NO974101D0 (en) 1997-09-05
EP0814813B1 (en) 2003-11-26
MX9706759A (en) 1997-11-29
CA2214406C (en) 2010-12-21
ATE254919T1 (en) 2003-12-15
HU226005B1 (en) 2008-02-28
AU701739B2 (en) 1999-02-04
AU5102296A (en) 1996-09-23
BR9607663A (en) 1998-06-16
HUP9800272A2 (en) 2000-05-28
CY2525B1 (en) 2006-02-08
DE69630876T2 (en) 2004-09-02
NO974101L (en) 1997-09-05
TR199700921T1 (en) 1998-02-21
PT814813E (en) 2004-04-30
KR19980702833A (en) 1998-08-05
CN1138545C (en) 2004-02-18

Similar Documents

Publication Publication Date Title
CA2263561A1 (en) Thienopyrimidines
CA2216796A1 (en) Quinazoline derivatives
AU650484B2 (en) Isoxazole compound, pharmaceutically acceptable salt thereof, and medicinal use thereof
CA2179015A1 (en) Use of bis(amidinobenzimidazoles) in the manufacture of medicament for inhibiting retroviral integrase
CY2525B1 (en) Use of penciclovir for the treatment of human herpes-virus-8
CA2120319A1 (en) Pharmaceutical for the treatment of skin disorders
GB9323404D0 (en) Pharmaceuticals
IL111138A (en) Pharmaceutical compositions comprising penciclovir and/or its bioprecursor and/or its derivatives for the treatment and prophylaxis of post-herpetic neuralgia
WO1986006960A3 (en) Use of nicorandil or pinacidil for the treatment of peripheral vascular disease
GB9323403D0 (en) Pharmaceuticals
AU8815091A (en) An imidazobenzodiazepine for the treatment of sleep disorders
EP1027894A3 (en) Pharmaceutical preparation for the treatment of inflammatory processes
MX9709438A (en) 3-hydroxy-pyridine-2-carboxylic ester amide acids, their preparation and use as medicaments.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96193793.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

WWE Wipo information: entry into national phase

Ref document number: 303951

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2214406

Country of ref document: CA

Ref document number: 2214406

Country of ref document: CA

Kind code of ref document: A

Ref document number: 1996 526607

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/006759

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1019970706240

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV1997-2831

Country of ref document: CZ

Ref document number: 97/00921

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 1996907360

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996907360

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1997-2831

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 1998 894929

Country of ref document: US

Date of ref document: 19980224

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1019970706240

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: 1019970706240

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996907360

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: PV1997-2831

Country of ref document: CZ